hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA
Authors
Aughton, K.Elander, N. O.
Evans, A.
Jackson, R.
Campbell, F.
Costello, E.
Halloran, C. M.
Mackey, J. R.
Scarfe, A. G.
Valle, Juan W
Carter, R.
Cunningham, D.
Tebbutt, N. C.
Goldstein, D.
Shannon, J.
Glimelius, B.
Hackert, T.
Charnley, R. M.
Anthoney, A.
Lerch, M. M.
Mayerle, J.
Palmer, D. H.
Buchler, M. W.
Ghaneh, P.
Neoptolemos, J. P.
Greenhalf, W.
Affiliation
Liverpool Experimental Cancer Medicine Centre, 2nd Floor Sherrington Building, Ashton St, University of Liverpool, Liverpool L69 3GE, UKIssue Date
2021
Metadata
Show full item recordCitation
Aughton K, Elander NO, Evans A, Jackson R, Campbell F, Costello E, et al. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA Vol. 13, Cancers. MDPI AG; 2021. p. 5758.Journal
CancersDOI
10.3390/cancers13225758PubMed ID
34830914Type
Articleae974a485f413a2113503eed53cd6c53
10.3390/cancers13225758
Scopus Count
Collections
Related articles
- Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
- Authors: Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W, European Study Group for Pancreatic Cancer
- Issue date: 2018 Apr
- Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
- Authors: Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR
- Issue date: 2009 Jan
- Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
- Authors: Shin DW, Lee JC, Kim J, Yoon YS, Han HS, Kim H, Hwang JH
- Issue date: 2021 Jun
- Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy.
- Authors: Okamura Y, Yasukawa S, Narimatsu H, Boku N, Fukutomi A, Konishi M, Morinaga S, Toyama H, Kaneoka Y, Shimizu Y, Nakamori S, Sata N, Yamakita K, Takahashi A, Kainuma O, Hishinuma S, Yamaguchi R, Nagino M, Hirano S, Yanagisawa A, Mori K, Uesaka K
- Issue date: 2020 Feb
- A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine.
- Authors: Kalloger SE, Riazy M, Tessier-Cloutier B, Karasinska JM, Gao D, Peixoto RD, Samimi S, Chow C, Wong HL, Mackey JR, Renouf DJ, Schaeffer DF
- Issue date: 2017 Jul